Abstract

This prospective, randomized, placebo-controlled trial tested green-lipped mussel oil (PCSO-524) added to sildenafil-based therapy in dogs with pulmonary hypertension (PH), mostly secondary to myxomatous mitral valve disease. After 70 days, owner-assessed exercise tolerance improved significantly in the PCSO-524 group (P = 0.009), and the improvement in coughing between Day 35 and Day 70 was greater than with placebo (P = 0.03). The tricuspid regurgitation pressure gradient (TRPG), an echocardiographic estimate of pulmonary arterial pressure, fell in all dogs (P = 0.001), with no difference between groups.